Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.
The disposition of tocainide following an i.v. infusion of tocainide HCl 100 mg was studied in 6 patients with decompensated cirrhosis (ascites) and renal dysfunction. In one patient with active hepatic necrosis the terminal plasma half-life was 57.4, and in the others the half life ranged from 16.0 to 29.0 h. The increase in half-life was correlated with biochemical evidence of renal dysfunction, but not with individual tests of hepatic function. Non-renal clearance of tocainide was similar to values reported previously in healthy subjects and patients with acute myocardial infarction. The apparent volume of distribution of tocainide was increased and the pattern of distribution was abnormal in some patients, as plasma concentrations increased after an initial fall and the elevated concentrations then persisted for several hours. This abnormality appeared to be most marked in patients with the greatest degree of liver dysfunction.
D000328:Adult; D000368:Aged; D003404:Creatinine / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007674:Kidney Diseases / Q000378:metabolism*; D007700:Kinetics; D008012:Lidocaine / Q000031:analogs & derivatives* / Q000378:metabolism; D008103:Liver Cirrhosis / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D016677:Tocainide
D016677:Tocainide; D008012:Lidocaine; D003404:Creatinine